Does GLP-1 Stop Working? Reasons and What to Do (October 2026)

01 · The core answer

Does GLP-1 really stop working?

For most people, no: what feels like the medicine stopping is usually a plateau or a change in circumstances. Weight loss on Mounjaro is not linear, and plateaus of a few weeks are normal and expected as the body adapts to a lower weight.¹ That is a very different situation from a medicine that has genuinely lost its effect.

Tirzepatide activates the GIP and GLP-1 receptors, which help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin.¹ Nothing in that mechanism implies a cliff-edge after which it simply switches off. What does change is the situation around it: you weigh less, your portions creep, your routine shifts, and the dose you need may not be the one you are on.

02 · Your next step

What to do if your progress has stalled

Start with the basics before assuming anything is wrong. Within the licence, the responses to a plateau are to review food intake honestly because portions drift back up, protect protein and activity, check the basics such as sleep and alcohol, and discuss with your prescriber whether a dose step-up is appropriate if you are not yet at maximum.¹

Just as important is what not to do. A plateau is not a reason to double doses or add unlicensed products.¹ Our guide on whether Mounjaro stops working goes through the same checks in more detail.

If you are already a customer, your monthly clinical review is the right place to raise a stall. If you are researching treatment, the Mounjaro pen starts at the 2.5mg dose and is reviewed by a GPhC-registered prescriber, with all strengths in stock. Our weight loss clinic page explains how the service works.

03 · Plateau or failure

Plateau or failure: how to tell the difference

A plateau is a pause in a treatment that is still working; failure means the medicine is giving you little or no benefit despite a proper dose and enough time. The two are easy to confuse because both show up as a flat line on the scales.

Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest, and most measurable progress builds from 5mg onward, month by month.¹ Trials measured results at 72 weeks, so think in months, not days, and judge progress by trend rather than individual weigh-ins.

Reaching a stable weight is also not the same as failing. If you have lost a meaningful amount and then level out, the medicine may simply be maintaining your new baseline. That is often the intended outcome of treatment rather than a sign it has stopped.

Some things point towards a plateau rather than failure: your appetite is still lower than before treatment, your clothes still fit differently, other measures such as waist size are still improving, and you have not changed dose or routine recently. In the trials, weight loss came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, which is why prescribers talk about health rather than only the number on the scales.² These are trial averages, not promises, but they are a reminder that the scales are only one signal.

04 · Dose level matters

Dose level: you may not be at your dose yet

One of the commonest reasons people feel the medicine is not working is that they are still on a starter or low dose. Mounjaro comes in six strengths, 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, and the dose ladder is designed to be climbed gradually rather than jumped.¹

Three months in, most people are still on the lower rungs, so trial-average losses at this stage are modest compared with the headline figures. In SURMOUNT-1, average weight loss built month by month, with the full averages measured at 72 weeks, not at twelve.² A sensible expectation at this point is mid single digits as a percentage of body weight, with wide individual variation. Slower early progress does not predict failure, because the dose you respond to may still be ahead of you.

The trial averages show a dose pattern too: in SURMOUNT-1 of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages and individual results vary. They do show why a prescriber may discuss a step-up rather than assume the medicine has run its course.

Higher is not automatically better for everyone. Your prescriber balances response against how well you tolerate each step, and the highest dose you can comfortably take may be below the top of the ladder. That is a legitimate maintenance dose, not a failure.

05 · Habits and food intake

Food intake, protein and everyday habits

Appetite suppression makes eating less feel easy at first, which can make it harder to notice when portions start to creep back. That is why an honest review of intake is the first thing a prescriber will ask about during a stall.

Treatment is used alongside a reduced-calorie diet and increased physical activity, not instead of them.¹ In practice, the checks that matter are simple. Are your meals still smaller than before treatment? Are snacks, drinks and alcohol adding calories you have stopped noticing? Are you protecting protein at each meal, so that you feel fuller and keep muscle? Are you sleeping well, since poor sleep tends to push appetite the wrong way?

A short run of food logging, even in a notes app or the free GLPTrackr companion app, can show patterns that memory misses. The aim is not perfection. It is to find out whether the plateau is the body adapting or the routine drifting.

Medicines also work differently from product to product. If you are comparing options, our page on whether orlistat stops working explains why a different kind of treatment stalls for different reasons.

06 · Activity and muscle

Activity: the part people drop first

Increased physical activity is part of the licence, not an optional extra. Nothing special is required: the evidence-backed pattern is regular moderate activity, such as brisk walking, plus resistance work for muscle.¹

Start where you are and build. On injection days with early side effects, lighter movement still counts. People often stop exercising when they feel tired or nauseated and never restart, which can quietly flatten progress.

Exercise also protects against regain if you later stop treatment, so it is worth building the habit while the medicine is helping you rather than waiting until afterwards. If you are unsure how to begin, say so at your next review; your prescribing team can point you to sensible starting points.

07 · Body adaptation

Body adaptation and returning hunger

As you lose weight, your body adapts to the lower weight, and progress slows even if you do everything the same. This is a normal biological response and one reason plateaus of a few weeks are expected.¹

Many people also describe hunger or "food noise" creeping back. There are several possible explanations: a missed or delayed injection, a dose that has become relatively low for you as your circumstances change, stress, poor sleep, or simply the natural variation in appetite across a treatment cycle. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle.

If hunger returns steadily and you have not missed doses, mention it at your review. It is useful information for your prescriber when deciding whether to hold, adjust or step up the dose.

08 · Why responses differ

Why some people respond less than others

Trial figures are averages, and individual results vary. In SURMOUNT-1 the averages were substantial, but individual outcomes spread widely around them, and some people lose far less than the headline figures.² A smaller response is not a personal failing and does not mean you did something wrong.

Experiences also differ from the very start. Some people notice appetite change and early loss in the first week, others feel little until a higher dose, and both are normal. Early loss includes water weight, so the trend over weeks matters more than any single weigh-in.²

Tolerability matters too. In SURMOUNT-1, 4.3% of people on 5mg, 7.1% on 10mg and 6.2% on 15mg stopped treatment because of side effects, compared with 2.6% on placebo.² If side effects are limiting your dose, that can limit your response, and it is worth telling your prescriber rather than quietly skipping injections.

Underlying health conditions and other medicines can also affect appetite and weight. Your prescriber can look at the whole picture, which is one reason ongoing reviews are valuable.

09 · Reviewing response

How your prescriber reviews response

Treatment response is formally reviewed, and there is a clear checkpoint. Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.¹

That checkpoint is about the highest tolerated dose, not simply the length of time you have been on treatment. If you are still working up the ladder, a prescriber will usually look at titration first. The question to ask at review is: am I on the right dose, and are my habits supporting it?

For people considering a switch between medicines, the decision belongs with a prescriber who can see your history. You can read how we frame the question of Mounjaro stopping working for weight loss, or how long any effect lasts in our guide to how long Mounjaro keeps working.

10 · Stopping and rebound

What happens when you stop

If you are asking whether the medicine stops working because you have stopped taking it, the evidence is clear: weight tends to return. Mounjaro manages weight; it does not cure the biology behind it.¹⁴

In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average.¹⁴ Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load.

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system, and there is no way to speed this up.¹ That is why appetite does not usually snap back overnight, but returns gradually as levels fall. Our guide on whether you can stop GLP-1 treatment covers planning an exit in more detail.

11 · Avoid unlicensed fixes

Fixes to avoid

When progress stalls, it is tempting to try shortcuts. The safest position is to stay within the licence.

Mounjaro is licensed as a once-weekly medicine, and its blood levels are designed around a 7-day cycle.

Likewise, a plateau is not a reason to double doses or add unlicensed products. Low-cost supplements sold with dramatic weight-loss claims have no clinical oversight and no place in a plan built on a licensed medicine. Talk to your clinical team rather than self-adjusting.

If you think a symptom is a side effect, report it through the Yellow Card scheme as well as telling your prescriber.¹⁹

12 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹